Latozinemab
Latozinemab (AL001) is a recombinant human anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research[1][2].
Product Specifications
CAS Number
2376132-27-1
Product Name Alternative
AL001
UNSPSC
12352203
Target
Neurotensin Receptor
Type
Inhibitory Antibodies
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Cancer-programmed cell death
Field of Research
Cancer; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/latozinemab.html
Purity
96.03
Solubility
H2O
Smiles
[Latozinemab]
Molecular Weight
(146.28 kDa)
References & Citations
[1]Kurnellas M, et al. Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia. J Transl Med. 2023 Jun 15;21 (1) :387. |[2]Ek M, et al. An anti-sortilin affibody-peptide fusion inhibits sortilin-mediated progranulin degradation. Front Immunol. 2024 Aug 8;15:1437886.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC402853-100 1x 100 µL
CD54 / ICAM-1 (15.2), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC402823-100 1x 100 µL
BMI1 (Oncogene and Stem Cell Marker) (BMI1/2823), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details